Daniel Vilarim Araujo: Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies
Daniel Vilarim Araujo, Medical Oncologist at shared on X:
“I’m thrilled to share our study, ‘Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies,’ now published in JCO Global Oncology
Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies | JCO Global Oncology
Authors: Iza Andrade de A. Souza, Beatriz de M. Dobbert, Barbara G. Sao Jose, Joao Pedro Homse-Netto, Larissa L. Furlan, Maira S. Abreu, Camila Ferrari, Bruno Uchoa, Kathia Abdallah, Stephano N. Lucio, Joao A. Soler, Fabio L.C. Fernandez, Luiza Ferreira, Joao D. Guedes, Aline F. Fares, and Daniel V. Araujo.
This study reflects the dedication and teamwork of everyone involved.
This work was Dr. Iza Souza’s fellowship project during her time at Hospital de Base. It was a true collaborative effort, from advocating with the Hospital Board to implementing the project on the ground.
Our findings show that low-dose anti-PD(L)1 agents are valid alternatives to standard label doses, offering real benefits to patients. This is the first report of low-dose anti-PD(L)1 use in Brazil and contributes to growing global evidence supporting this approach.
Finally, we advocate for the consideration of low-dose anti-PD(L)1 in settings where standard label doses may be unaffordable. This approach could expand access and improve outcomes in resource-limited environments!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023